Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Resverlogix Corp. (OTC: RVXCF).

Full DD Report for RVXCF

You must become a subscriber to view this report.


Recent News from (OTC: RVXCF)

Your Daily Pharma Scoop: Resverlogix Cleared For Trial, ViiV Positive Data, Eli Lilly Up
Analysis Focus: RVXCF Resverlogix ( OTCPK:RVXCF ) recently announced that the FDA has accepted the statistical analysis plan and endpoints for the large-scale Phase 3 trial of assessment of cardiovascular benefits of its lead candidate apabetalone. The projected endpoint of the study is ...
Source: SeekingAlpha
Date: June, 16 2018 10:01
FDA on board with Resverlogix BETonMACE study
Resverlogix ( OTCPK:RVXCF ) announces that the FDA has confirmed that its statistical analysis plan and endpoints for the large-scale Phase 3 BETonMACE study to assess the cardiovascular benefits of lead drug apabetalone in cardiovascular disease patients with type 2 diabetes and low hig...
Source: SeekingAlpha
Date: June, 14 2018 16:25
Resverlogix (RVXCF) Presents At 2018 Bloom Burton & Co. Healthcare Investor Conference - Slideshow
The following slide deck was published by Resverlogix Corp. in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 03 2018 13:26
TSX extends review of Resverlogix's compliance with listing requirements
Resverlogix ( OTCPK:RVXCF -0.3% ) reports that the Toronto Stock Exchange (TSX) has extended its review to no later than May 14 of the company's compliance with listing requirements. More news on: Resverlogix Corp., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 12 2018 09:55
Resverlogix announces US$30M loan commitment letter
Resverlogix ( OTCPK:RVXCF ) has accepted a commitment letter for a US$30M senior secured loan with Third Eye Capital. The Loan will have a term of 12 months, repayable in part or in whole at any time with interest of 10% per annum. More news on: Resverlogix Corp., Healthcare stocks news,...
Source: SeekingAlpha
Date: April, 11 2018 07:42
Resverlogix (RVXCF) Presents At BIO CEO & Investor Conference - Slideshow
The following slide deck was published by Resverlogix Corp. in conjunction with this Read more ...
Source: SeekingAlpha
Date: February, 13 2018 14:07
FDA accepts Amicus' migalastat NDA for Fabry; action date August 13; shares up 4% premarket
The FDA accepts for review Amicus Therapeutics' (NASDAQ: FOLD ) marketing application seeking approval for migalastat HCL for the treatment of patients at least 16 years old with Fabry disease who have certain genetic mutations. The agency's action date is August 13. More news on: Amicus...
Source: SeekingAlpha
Date: February, 12 2018 07:47
Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold
Content Analysis of coverage: ACRS Stocks in the news: EGLT, TSRO Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Daily Trade Idea: (for TPT Subscribers only) Subscriber Questions & Answers (for T...
Source: SeekingAlpha
Date: December, 17 2017 16:15
Resverlogix reports Q2 results
Resverlogix ( OTCPK:RVXCF ): Q2 EPS of $0.10 Press Release More news on: Resverlogix Corp., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: December, 14 2017 23:17
Resverlogix (RVXCF) Investor Presentation - Slideshow
The following slide deck was published by Resverlogix Corp. in conjunction with this Read more ...
Source: SeekingAlpha
Date: December, 13 2017 14:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-132.6752.332.6752.2718,947
2018-12-122.302.362.392.3023,958
2018-12-112.272.272.322.247851,375
2018-12-102.202.272.532.2083,825
2018-12-072.2552.332.402.25534,882

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-139,42718,94749.7546Short
2018-12-1212,35823,95851.5819Short
2018-12-1127,77551,37554.0633Short
2018-12-1035,82583,82542.7378Short
2018-12-0715,00734,88243.0222Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RVXCF.


About Resverlogix Corp. (OTC: RVXCF)

Logo for Resverlogix Corp. (OTC: RVXCF)

Not available

 

Contact Information

 

 

Current Management

  • Donald A. McCaffrey / President, CEO
  • A. Brad Cann / CFO
  • Sarah Zapotichny / Director, Inv. Rel.
  • Peter Johann / Chairman

Current Share Structure

  • Market Cap: $92,763,104 - 03/15/2018
  • Issue and Outstanding: 74,210,483 - 10/31/2012

 



Daily Technical Chart for (OTC: RVXCF)

Daily Technical Chart for (OTC: RVXCF)


Stay tuned for daily updates and more on (OTC: RVXCF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RVXCF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RVXCF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RVXCF and does not buy, sell, or trade any shares of RVXCF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/